A PHASE 2A, OPEN-LABEL, SINGLE-ARM STUDY TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF VX-407 IN SUBJECTS WITH AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE WHO HAVE A SUBSET OF PKD1 GENE VARIANTS
- Registry ID
- VX24-407-101
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Phase
- PHASE2
- Study type
- INTERVENTIONAL
- Sponsor
- VERTEX PHARMACEUTICALS (CANADA) INCORPORATED
- Start date
- 2025-11-21
- Last update
- 2025-08-28
Conditions
Related clinical trials
- PODOMOUNT-BASKET, A PHASE II, MULTICENTRE, RANDOMISED, 2-ARM PARALLEL-GROUP, DOUBLE-BLIND, PLACEBO-CONTROLLED BASKET TRIAL TO ASSESS SAFETY, TOLERABILITY, PK, AND EFFICACY OF BI 764198 IN FOUR PROTEINURIC KIDNEY DISEASES
- BLEEDING REDUCTION IN ACUTE AND CHRONIC KIDNEY PATIENTS HAVING SURGERY
(BRACKETS) PILOT TRIAL
- A PHASE IIB, MULTICENTRE, RANDOMISED, DOUBLE-BLIND, DOSE-FINDING STUDY TO EVALUATE THE EFFICACY, SAFETY AND TOLERABILITY OF BALCINRENONE IN COMBINATION WITH DAPAGLIFLOZIN COMPARED WITH DAPAGLIFLOZIN IN PATIENTS WITH CHRONIC KIDNEY DISEASE AND ALBUMINURIA
- CANAGLIFLOZIN IN PATIENTS WITH ADVANCED RENAL DISEASE WITH MRI ENDPOINTS (CARE-MRI TRIAL)
- A PHASE III, RANDOMISED, MULTICENTRE, DOUBLE-BLIND STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF ZIBOTENTAN/DAPAGLIFLOZIN COMPARED TO DAPAGLIFLOZIN ALONE IN PARTICIPANTS WITH CHRONIC KIDNEY DISEASE AND HIGH PROTEINURIA
- A PHASE 2B / 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, COMBINED DOSE-FINDING AND CARDIOVASCULAR OUTCOME STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF CSL300 IN SUBJECTS WITH END STAGE KIDNEY DISEASE UNDERGOING DIALYSIS
View on source registry